BioWa, Inc. (BioWa) and Oxford BioTherapeutics Ltd (OBT) have announced that they have entered into a license agreement to provide OBT with access to BioWa’s patented POTELLIGENT® Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.
OBT intends to use POTELLIGENT® Technology to develop, manufacture and commercialise selected ADCC programs from its pipeline of preclinical antibodies for oncology which it has built based upon novel targets identified using its OGAP® proteomic database.
In return for the license, OBT will pay to BioWa undisclosed license fees, development and commercialisation milestones and royalties on sales of any products that it commercialises.
“We are delighted to have access to BioWa’s POTELLIGENT® Technology as part of our technology access portfolio as we build a pipeline of first-in-class therapeutic antibodies for cancer” said Christian Rohlff, CEO of OBT. “Our strategy is to combine novel proprietary oncology targets with world-leading antibody technologies, such as POTELLIGENT® Technology, to develop highly efficacious new cancer drugs for patients with few treatment options.”
“The OBT cancer specific antibody portfolio has matured to an advanced stage where coupling to BioWa’s POTELLIGENT® Technology enhances already promising anticancer agents and further enables our clinical development pipeline”, commented OBT’s Senior Vice President of Oncology, Jon Terrett.
“We are excited to expand our set of small company arrangements with OBT. In large part, our decision to partner with OBT was driven by our interest in novel therapeutic antibody targets identified through the OGAP® proteomic database,” said Yasunori Yamaguchi, President and CEO of BioWa.